Compare ARK Genomic Revolution ETF (ARKG) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs ProShares UltraPro S&P500 — how do they compare? ARK Genomic Revolution ETF trades at $40.68, while ProShares UltraPro S&P500 trades at $145.01. Which is the better fit depends on your goals.
| ARKG | UPRO | |
|---|---|---|
Sector | Sector/Thematic | Leveraged / Inverse |
52-Week High | $43.57 | $150.93 |
52-Week Low | $23.09 | $89.29 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
UPRO trades at $146.15, up 1.21% with a bullish technical outlook from moving averages. The stock shows neutral oscillator signals with RSI at 53.33 suggesting balanced momentum. Recent news highlights S&P 500 momentum driven by AI infrastructure spending and strong earnings expectations, though Fed policy and geopolitical risks create volatility. The dividend of $0.30 is scheduled for June 2026.
The stock benefits from AI-driven market tailwinds but faces valuation concerns and sector rotation risks. Earnings growth remains the key catalyst, though stretched valuations and Fed tightening pose headwinds. Institutional sentiment appears cautiously optimistic given the technical strength and sector momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
